139 related articles for article (PubMed ID: 33341239)
1. Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial.
Fachini AMD; Zuliani AC; Sarian LO; Teixeira JC; Esteves SCB; da Costa Machado H; Zeferino LC
Gynecol Oncol; 2021 Feb; 160(2):379-383. PubMed ID: 33341239
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
Shrivastava S; Mahantshetty U; Engineer R; Chopra S; Hawaldar R; Hande V; Kerkar RA; Maheshwari A; Shylasree TS; Ghosh J; Bajpai J; Gurram L; Gulia S; Gupta S;
JAMA Oncol; 2018 Apr; 4(4):506-513. PubMed ID: 29423520
[TBL] [Abstract][Full Text] [Related]
3. Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: a randomized controlled trial.
Zuliani AC; Esteves SC; Teixeira LC; Teixeira JC; de Souza GA; Sarian LO
J Clin Oncol; 2014 Feb; 32(6):542-7. PubMed ID: 24449243
[TBL] [Abstract][Full Text] [Related]
4. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C
Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158
[TBL] [Abstract][Full Text] [Related]
5. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer.
Shaverdian N; Gondi V; Sklenar KL; Dunn EF; Petereit DG; Straub MR; Bradley KA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):562-8. PubMed ID: 23561652
[TBL] [Abstract][Full Text] [Related]
6. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
7. High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone.
Milosevic MF; Pintilie M; Hedley DW; Bristow RG; Wouters BG; Oza AM; Laframboise S; Hill RP; Fyles AW
Int J Cancer; 2014 Oct; 135(7):1692-9. PubMed ID: 23904154
[TBL] [Abstract][Full Text] [Related]
8. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
Binbin T; Lingying W; Manni H; Jusheng A; Ning L
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
[TBL] [Abstract][Full Text] [Related]
9. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
10. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
11. Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy.
Gennigens C; De Cuypere M; Seidel L; Hermesse J; Barbeaux A; Forget F; Albert A; Jerusalem G; Kridelka F
Cancer Med; 2020 Nov; 9(22):8432-8443. PubMed ID: 32954675
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
13. Comparison of therapeutic effects of chemo-radiotherapy with neoadjuvant chemotherapy before radical surgery in patients with bulky cervical carcinoma (stage IB3 & IIA2).
Akhavan S; Alibakhshi A; Parsapoor M; Alipour A; Rezayof E
BMC Cancer; 2021 Jun; 21(1):667. PubMed ID: 34088300
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of post-radiation serum squamous cell carcinoma antigen and primary tumor regression for cervical squamous cell carcinoma.
Wan Q; Yan W; Liu Y; Lin Y; Lu Z
Cancer Biomark; 2020; 29(3):327-335. PubMed ID: 32716344
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of treatment results and prognostic factors in early-stage cervical carcinoma patients treated with postoperative radiotherapy or radiochemotherapy.
Demirci S; Ozsaran Z; Ozsaran A; Yavas F; Demircioglu B; Hanhan M; Dikmen Y; Aras AB
Eur J Gynaecol Oncol; 2012; 33(1):62-7. PubMed ID: 22439408
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
18. The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy.
Onal C; Yildirim BA; Guler OC; Mertsoylu H
Int J Gynecol Cancer; 2018 Oct; 28(8):1553-1559. PubMed ID: 30247248
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
20. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
